Scientist, mammalian platform development

Ginkgo’s mission is to make biology easier to engineer. We are constructing, editing, and redesigning the living world in order to answer the globe’s growing challenges in health, energy, food, materials, and more. Our bioengineers make use of an in-house automated foundry for designing and building new organisms. Ginkgo is continuously crossing new frontiers of biological engineering and we have a record of delivering what was, until recently, thought impossible. Now, our expansion into mammalian cell engineering promises to push our boundaries even further, and so we’re looking for pioneering engineers to make Ginkgo’s new mammalian cell foundry a success. While cell and gene therapies have seen remarkable success in the clinic, we are at the dawn of a new age in our ability to precisely control gene expression. To do this well, we need to build out our mammalian editing platform with your help. We have a strong microbial platform that serves diverse hosts, and we need you to help us scale what we have to include cell therapy and viral gene therapy in eukaryotic cell lines. Should we build a new version, adapt what we have or acquire new technology? We'll need your experience and insight to show us the way. You'll need to work collaboratively with a variety of folks to get this done, including our amazing software engineers, automation engineers and junior researchers. You'll need excellent written and oral communication skills to ensure that your ideas are well understood by a diverse audience. We are excited to have you onboard! To learn more about Ginkgo, check out some recent press: What is it really like to take your company public via a SPAC? One Boston biotech shares its journey (Fortune) Ginkgo Bioworks resizes the definition of going big in biotech, raising $2.5B in a record SPAC deal that weighs in with a whopping $15B-plus valuation (Endpoints News) Ginkgo Bioworks CEO on scaling up Covid-19 testing: ‘If we try, we can win’ (CNBC) Ginkgo raises $70 million to ramp up COVID-19 testing for employers, universities (Boston Globe) Ginkgo Bioworks Redirects Its Biotech Platform to Coronavirus (Wall Street Journal) Ginkgo Bioworks Provides Support on Process Optimization to Moderna for COVID-19 Response (PRNewswire) The Life Factory: Synthetic Organisms From This $1.4 Billion Startup Will Revolutionize Manufacturing (Forbes) Synthetic Bio Pioneer Ginkgo Raises $290 Million in New Funding (Bloomberg) Ginkgo Bioworks raises $350 million fund for biotech spinouts (Reuters) Can This Company Convince You to Love GMOs? (The Atlantic) We also feel that it’s important to point out the obvious here – there’s a serious lack of diversity in our industry, and that needs to change. Our goal is to help drive that change. Ginkgo is deeply committed to diversity, equity, and inclusion in all of its practices, especially when it comes to growing our team. Our culture promotes inclusion and embraces how rewarding it is to work with people from all walks of life.   We’re developing a powerful biological engineering platform, so we must remain mindful of the many ways our technology can – and will – impact people around the world. We care about how our platform is used, and having a diverse team to build it gives us the best chance that it’s something we’ll be proud of as it continues to grow. Therefore, it’s critical that we incorporate the diverse voices and visions of all those who play a role in the future of biology. It is the policy of Ginkgo Bioworks to provide equal employment opportunities to all employees and employment applicants.